A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence

This study has been withdrawn prior to enrollment.

(Lack of enrollment)

Sponsor:

ClinicalTrials.gov Identifier:

NCT01272258

First Posted: January 7, 2011

Last Update Posted: February 2, 2017

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Information provided by (Responsible Party):

CytoDyn, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study

Study was withdrawn before participants were enrolled.

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been withdrawn prior to enrollment.
Estimated Study Completion Date:	February 2017
Estimated Primary Completion Date:	January 2017 (Final data collection date for primary outcome measure)

To Top